• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Staar Surgical settles class action suit for $7m

Staar Surgical settles class action suit for $7m

March 2, 2018 By Sarah Faulkner

Staar SurgicalStaar Surgical (NSDQ:STAA) inked a $7 million deal last year to settle claims that the company misled investors regarding regulatory violations spotted by the FDA at a Monrovia, Calif.-based manufacturing facility.

The plaintiff, Edward Todd, initially alleged that Staar Surgical, ex-president & CEO Barry Caldwell, CFO Deborah Andrews and ex-CFO Stephen Brown failed to disclose problems that eventually resulted in a warning letter from the FDA in 2014.

In the May warning letter, inspectors wrote that the company was missing design files for its Visian implantable lenses and that Staar Surgical had insufficient record-keeping, lack of risk analysis documentation and poor customer complaint management.

Later that year, Todd filed a putative securities class action suit against the company and its executives in the U.S. District Court of Central California.

In October of 2014, Todd amended his complaint, reducing the alleged class period to Nov. 1, 2013 – Sept. 29, 2014 and demanding compensatory damages as well as attorneys’ fees.

Staar Surgical agreed to settle the case and in October last year, the court issued a final approval for the $7 million class action settlement deal, according to Staar Surgical’s annual report.

Also this week, Staar Surgical reported losses of $138,000, or 0¢ per share, on sales of $24.9 million for the three months ended Dec. 29. The company reeled in its losses by 17.4% while sales grew 12.3% compared with the same period last year.

Losses per share were ahead of estimates on The Street, where analysts were looking for sales of $23.9 million.

Staar Surgical posted losses of $2.1 million for the full year, or 5¢ per share, on sales of $90.6 million, seeing losses shrink by 82.4% on sales growth of 9.9% compared with the same period last year.

Filed Under: Legal News, Optical/Ophthalmic, Wall Street Beat Tagged With: STAAR Surgical Co

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy